To review clinical experience with methicillinresistant Staphylococcus aureus (MRSA) in tertiary-care hospitals in Jeddah, Saudi Arabia.
infection; the rest represented colonization. Surgical wounds (35.2%), the chest (29%), and central venous catheters (13%) were the most common sites of infection. Bacteremia occurred in 15.4% of patients. Local signs (84%) and fever (75.9%) were the most common clinical manifestations. Respiratory distress and septic shock occurred in 30.2% and 13.6% of cases, respectively. Of 162 patients with MRSA infection and 60 patients with MRSA colonization, 95.7% and 70% received antibiotics in the preceding 6 weeks, respectively (P<.0001). The total mortality of patients with MRSA infection was 53.7%: 36.4% as a result of MRSA infection and 17.3% as a result of other causes.
CONCLUSIONS:
The prevalence of MRSA is high and rapidly increasing in the two hospitals, as it is worldwide. Control measures to prevent the spread of MRSA in hospitals should continue, with reinforcement of hygienic precautions and development of policies to restrict the use of antibiotics (Infect Control Hosp Epidemiol 2001;22:211-216).
Methicillin-resistant Staphylococcus aureus (MRSA)
is primarily a nosocomial pathogen that emerged in the 1980s as a major cause of infection and colonization in hospitalized patients. 1 More recently, this organism has been implicated as a cause of community-acquired infections in individuals with a recognized predisposing risk factor, such as recent contact with a healthcare facility, nursing home residence, or parenteral substance abuse. 2, 3 Communityacquired MRSA infections in the absence of identified risk factors also have been reported increasingly. [3] [4] [5] [6] The prevalence of MRSA has increased worldwide over the past decade, with marked variations in different regions. It is generally high in the United States, 7 southern European countries, 8 and Japan, 9 but is low in Sweden, Denmark, and The Netherlands. 8, 10, 11 A high prevalence of MRSA also has been reported from Malaysia, 12 Latin America, 13 Ethiopia,
Microbiological Methods
S aureus was identified using routine bacteriological procedures. Susceptibility testing of S aureus isolates to oxacillin was performed using the 1-µg oxacillin disk-diffusion method (Oxoid Limited; Basingstoke, Hampshire, England, for KAUH; Mast Diagnostics; Mast Group Ltd, Merseyside, UK, for KFH) according to published guidelines. 16 Oxacillin resistance was demonstrated by a zone of inhibition of 10 mm or less. Strains with a borderline zone of inhibition (11-12 mm) were tested by E-test (AB Biodisk; Dalvagen, Solna, Sweden) to determine the minimum inhibitory concentration (MIC). Strains with MICs of 4 µg/mL or greater were considered resistant; 2 µg/mL or less, sensitive; and between 2 and 4 µg/mL, intermediate. 17 Susceptibility testing to other antibiotics was not performed routinely.
Definitions
MRSA isolates were considered community isolates if they were recovered within 72 hours of admission and nosocomial if they were recovered beyond that period.
The clinical significance of MRSA isolation from different body specimens was classified into either infection or colonization, based on the presence or absence of a potential source of MRSA infection, the patient's clinical status, and other relevant data. In the absence of any potential source or clinical evidence of infection, MRSA was considered to be colonizing the site from which a specimen was obtained.
The source of infection was determined on the basis of clinical evidence and recovery of MRSA from an infected site.
Outcome of patients with MRSA infection was classified into four categories: recovery without complications, recovery following complications such as septic shock or respiratory failure, death due to MRSA infection, or death unrelated to MRSA infection.
Data Analysis
The Statistical Package for Social Science (SPSS) program (release 7.5.1; SPSS Inc, Chicago, IL, 1996) was used for data analysis. The chi-square test was used for comparison of proportions.
RESULTS
The total number of S aureus isolates during the study period was 673, of which 222 (33%) were MRSA isolated from 222 patients, representing 6.8 (222/32,445ϫ1,000) MRSA isolates per 1,000 admissions. Thirty-five isolates (15.8%) were community isolates, and 187 isolates (84.2%) were nosocomial. Table 1 8 .6%), chronic obstructive pulmonary disease (10 patients, 4.5%), heart failure (9 patients, 4.1%), and human immunodeficiency virus infection (3 patients, 1.4%).
The clinical features and outcome of MRSA infections at the two hospitals are shown in Table 2 . MRSA caused infection in 162 (73%) cases, and in the remaining 60 (27%) patients, it represented colonization. The sites of MRSA infection included surgical-wound infections (57 patients, 35.2%), pneumonia (47 patients, 29%), central venous catheter infections (21 patients, 13%), urinary tract infections (13 patients, 8%), and peripheral venous catheter infections (11 patients, 6.8%). Bacteremia occurred in 25 patients (15.4%). Local signs (136 patients, 84%) such as erythema, purulent discharge or tenderness of wounds or intravenous catheters' sites, and fever (123 patients, 75.9%) were the most common clinical manifestations of MRSA infection. Respiratory distress and septic shock occurred in 49 (30.2%) and 22 (13.6%) patients, respectively. Of 162 patients with MRSA infection and 60 patients with MRSA colonization, 155 (95.7%) and 42 (70%) received antibiotics in the preceding 6 weeks, respectively (odds ratio, 9.5; 95% confidence interval, 3.5-27; P<.001).
A total of 75 (46.3%) of 162 patients with MRSA infections completely recovered from their infections; 48 (29.6%) had uneventful recovery, whereas the remaining 27 (16.7%) recovered following complications such as septic shock or respiratory failure requiring mechanical ventilation. The total mortality of patients with MRSA infection was 53.7% (87/162); 36.4% (59/162) died as a result of MRSA infection, and 17.3% (28/162) as a result of other diseases ( Table 2) .
The demographic, epidemiological, and clinical characteristics of patients in the two hospitals were comparable 
DISCUSSION
In the United States, the prevalence of MRSA increased from 2% of S aureus isolates in 1974 to approximately 50% in 1997. 18, 19 In England and Wales, resistance to methicillin among S aureus isolated from blood or cerebrospinal fluid was stable at approximately 1.5% of isolates during 1989 and 1991, but increased thereafter to 13.2% in 1995. 20 Currently, in UK hospitals, prevalence of MRSA has reached epidemic levels, and incidents involving MRSA have risen 12-fold since 1991. In 1999, MRSA represented 37% of all S aureus infections, compared with only 3% in 1991. 21 A prevalence of more than 30% also was observed in southern European countries such as Spain, France, and Italy. 8 This study at KAUH and KFH demonstrated a high prevalence of MRSA (33% of all S aureus isolates). At KAUH the prevalence gradually has increased from less than 2% in 1988 (unpublished data) to the current rate of 38%. Similarly, at KFH the prevalence increased from 15% in 1994 (unpublished data) to the current rate of 29.1%. The organism affected all age groups, with more than one fourth of patients being 60 years of age or above. At KAUH almost one half of the patients were in the "extremes of age" group (р1 or у60 years of age). There was no predilection for any gender or nationality at KAUH, whereas at KFH, male and Saudi patients were more than two times as commonly affected as female and non-Saudi patients. This male Saudi preponderance at KFH is explained by the fact that approximately three quarters of 13,953 patients admitted to KFH during the study period were Saudi men.
More than three quarters of cases were nosocomial, and the rest were community isolates. The prevalence in the ICU was 10.8% at KAUH, compared to 42.3% at KFH. The high prevalence of MRSA infection and colonization in the ICU at KFH is likely to be due to a break in the standard infection control measures.
Once confined mainly to hospitals, MRSA has been increasingly implicated in community-acquired infections and colonization in patients with predisposing risk factors, such as recent contact with a healthcare facility, nursing home residence, or parenteral substance abuse, 2,3 as well as in patients without any recognized predisposing risk factor. [3] [4] [5] [6] In two hospitals in the United States in the early 1990s, 28% to 67% of patients with MRSA colonization had probable community acquisition. 22, 23 In five Canadian tertiary acute-care teaching hospitals in three provinces, patients with MRSA detected at admission accounted for 62% of MRSA isolations from 1990 through 1992. 5 In a US university hospital, 36 (41%) of 87 patients with MRSA had community acquisition; of these, 8 (22%) had no identified risk factors. 24 In a US pediatric hospital, 8 and 35 cases of community-acquired MRSA infections were identified in the time periods 1988 through 1990 and 1993 through 1995, respectively. One (12.5%) and 25 (71.4%) cases had no identified risk factors, respectively, and the prevalence of community-acquired MRSA without identified risk increased from 0.1 per 1,000 admissions from 1988 through 1990 to 2.6 per 1,000 admissions from 1993 through 1995. 6 The prevalence of community isolates of MRSA in our study (15.8% of all MRSA isolates, or 1.1/1,000 admissions) is moderately high when compared to published data. These studies, collectively, indicate that MRSA now may be more widespread in the general population than has been appreciated previously.
Risk factors that have been associated with MRSA acquisition include older age, prolonged hospitalization, prior antibiotic therapy, more severe underlying disease and degree of disability, surgical procedures, presence in an ICU or burn unit, having a surgical-wound infection, intravascular devices, mechanical ventilation, tracheostomy, pressure ulcers, or exposure to other infected or colonized individuals. 1, 25, 26 Not only does antibiotic therapy predispose to colonization with MRSA, but it also increases the risk of invasive disease and infection, as demonstrated by this study where significantly more patients with MRSA infection than those with MRSA colonization received antibiotics prior to positive MRSA culture (95.7% vs 70%; P<.001). Other host factors associated with progression from colonization to infection include recent prior hospitalization, preceding surgery or wound debridement, and the number of invasive procedures. 27 Approximately three quarters of cases represented infection, and the remainder represented colonization. This high infection-to-colonization ratio has been observed by other researchers. For instance, in an American MRSA outbreak, 260 (90.9%) of 286 affected patients were infected and not simply colonized. 28 Healthcare facilities that routinely perform MRSA surveillance cultures, which were not undertaken in either center during this study period, obviously have substantially lower infection-to-colonization ratios due to detection of more colonized patients. Therefore, this information is essential for appropriate comparison of MRSA prevalence and infection-to-colonization ratios of different centers.
Bacteremia and septic shock occurred in 15.4% and 13.6% of cases with MRSA infections, respectively. The total mortality of patients with MRSA infections was high (53.7%), as was the mortality attributable to MRSA infection (36.4%). It was generally believed that MRSA strains are not more virulent than methicillin-susceptible (MSSA) strains. 19, 29, 30 Recent reports, however, have suggested that MRSA bacteremia was associated with a significantly higher mortality rate than MSSA bacteremia. 31, 32 For instance, Romero-Vivas et al compared 100 cases of MSSA bacteremia and 84 cases of MRSA bacteremia; the mortality rates were 32% and 58.3%, respectively (P<.01), and methicillin resistance was found to be associated independently with mortality. 31 Vancomycin has been the drug of choice for MRSA infections for the past 2 decades. Recent reports, however, described strains of MRSA that were intermediately resistant to glycopeptides (glycopeptide-intermediate S aureus [GISA] ) and that were associated with therapeutic failure of vancomycin. Such strains have been reported from Japan, 33, 34 the United States, 35 Europe (France, the United Kingdom, and Spain), and the Far East (Hong Kong and Korea). 36 The isolates from the United States, France, and strain Mu50 from Japan appear to have developed from preexisting MRSA infections. 36 The isolation of such strains from several parts of the world suggests that GISA will continue to emerge worldwide, portending the emergence of MRSA strains for which there will be no effective therapy, a situation similar to that in the pre-antibiotic era.
In conclusion, the prevalence of MRSA is high and rapidly increasing in the two tertiary-care centers in Jeddah, Saudi Arabia, as it is worldwide. One can foresee a time in the near future when the majority of S aureus isolates would be resistant to methicillin, as happened with penicillin, to which most isolates of S aureus now are currently resistant. Spread of vancomycin resistance among MRSA is also fearfully expected. Attempts to control the spread of MRSA in hospitals therefore should continue, with reinforcement of hygienic precautions and infection control measures. 37 Hospitals also should develop policies to restrict the use of antibiotics and establish monitoring systems for rapid identification of epidemics and determination of factors responsible for spread and colonization, to allow for a more targeted approach.
New Agents Cause Nosocomial Fungemia

Gina Pugliese, RN, MS Martin S. Favero, PhD
The primary cause of nosocomial fungemia has been Candida species, but increasingly molds and other yeasts are being implicated in disease. Exophiala jeanselmei and members of the genus Rhinocladiella are dematiaceous molds, which have been associated infrequently with systemic infection and have not been described as causes of fungemia. Nucci and coinvestigators from Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Brazil, recently reported the occurrence of 23 cases of fungemia due to these organisms over a 10-month period. They also describe the clinical characteristics of patients and outcomes.
The majority of patients were immunosuppressed; 21 (91%) of 23 had received blood products, and 78% had a central venous catheter. All patients had at least one manifestation of fever, but only 1 patient had signs or symptoms suggesting deep-seated infection. Antifungal therapy was given to 19 of the 23 patients; of those who did not receive therapy, 3 died prior to the culture result, and 1 had been discharged without therapy. 
